{"analyses":[{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.10","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3360","paramType":"Hazard Ratio (HR)","paramValue":"0.91","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.4","upperLimit":"27.0","value":"23.3"},{"groupId":"OG001","lowerLimit":"18.4","upperLimit":"24.5","value":"21.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"322"}],"units":"Participants"}],"description":"Duration of survival was defined as the time between the date of randomization and date of death due to any cause. Participants still alive at the time of analysis were censored at the date they were last known to be alive. Kaplan-Meier estimates were used for analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bevacizumab infusions were administered every two weeks at a dose of 10 mg/kg for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.","id":"OG000","title":"Bevacizumab + IFN-Alfa-2A"},{"description":"Placebo matched with Bevacizumab infusions were administered every two weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.","id":"OG001","title":"Placebo + IFN-Alfa-2A"}],"paramType":"MEDIAN","populationDescription":"ITT population included all participants randomized into the study.","reportingStatus":"POSTED","timeFrame":"Baseline until death (up to 4.25 years)","title":"Overall Survival (OS) Duration","type":"PRIMARY","unitOfMeasure":"months"}